Zoladex (Goserelin Acetate): Indications, Dosing, and Adverse Effects
Zoladex (goserelin acetate) is a GnRH agonist used for ovarian suppression in premenopausal women with hormone receptor-positive breast cancer, palliative treatment of advanced prostate cancer, endometriosis management, endometrial thinning before ablation, and palliative treatment of advanced breast cancer in pre/perimenopausal women. 1
Primary Indications
Breast Cancer (Premenopausal Women)
- Hormone receptor-positive early breast cancer: Combined with tamoxifen or aromatase inhibitors for ovarian function suppression 2, 3
- Advanced breast cancer: Palliative treatment in pre- and perimenopausal women 1
- Particularly indicated for higher-risk patients (young age, high-grade tumors, lymph node involvement) 3
Prostate Cancer
- Locally confined carcinoma: Combined with flutamide 1
- Advanced/metastatic disease: Palliative treatment as monotherapy 4, 1
Gynecologic Conditions
- Endometriosis: Management for 6 months maximum in women ≥18 years 1
- Dysfunctional uterine bleeding: Endometrial thinning before ablation 1
Dosing Regimens
Standard Formulations
3.6 mg depot: Administered subcutaneously every 28 days (4 weeks) 3, 1
- Used in SOFT, TEXT, and ABCSG-12 trials for breast cancer 2
- Standard dose for endometriosis and endometrial thinning 1
10.8 mg depot: Administered subcutaneously every 12 weeks (3 months) 3, 1
- Non-inferior to monthly 3.6 mg dosing for estradiol suppression 5
- Reduces injection burden while maintaining efficacy 6, 7
Administration Details
- Inject subcutaneously into upper abdominal wall 1
- Critical warning: Exercise extra care in patients with low BMI or receiving full-dose anticoagulation due to risk of injection site hemorrhage 1
Duration of Treatment
Breast cancer ovarian suppression: 5 years optimal duration based on SOFT/TEXT trials 3
- Minimum 2 years recommended (8-year DFS: 85.4% with OFS + tamoxifen vs 80.2% with tamoxifen alone) 3
Endometriosis: Maximum 6 months due to hypoestrogenic effects 1
Prostate cancer: Lifelong for advanced disease 4
Common Adverse Effects
Men with Prostate Cancer (>10% incidence)
- Hot flashes (most common) 1
- Sexual dysfunction and decreased erections 1
- Lower urinary tract symptoms 1
- Gynecomastia and breast tenderness 1
Women (>20% incidence across indications)
The adverse event profile is similar for breast cancer, endometriosis, and dysfunctional uterine bleeding 1:
- Hot flushes (67-93% in various studies) 1, 7, 8
- Headache
- Sweating/night hyperhidrosis (90%) 8
- Acne
- Emotional lability and depression 1
- Decreased libido
- Vaginitis
- Breast atrophy
- Seborrhea
- Peripheral edema
Serious Adverse Effects and Warnings
Tumor flare phenomenon (first 2-3 weeks): Transient worsening of cancer symptoms due to initial testosterone surge 4, 1
- May cause ureteral obstruction or spinal cord compression in prostate cancer 1
- Monitor high-risk patients closely during initiation 1
Cardiovascular risks: Increased risk of myocardial infarction, sudden cardiac death, and stroke in men receiving GnRH analogs 1
Metabolic effects:
- Hyperglycemia and increased diabetes risk—monitor blood glucose 1
- Hypercalcemia in patients with bone metastases 1
QT prolongation: Consider risks vs benefits in patients with congenital long QT syndrome, heart failure, or electrolyte abnormalities 1
Bone loss: Rapid osteopenia/osteoporosis development 9
- Consider bisphosphonates (zoledronic acid 4 mg every 6 months) for prevention 9, 10, 9
- ABCSG-12 trial showed goserelin plus tamoxifen/anastrozole caused significant bone loss without concurrent bisphosphonate 9
Depression: May occur or worsen in women; monitor carefully, especially those with depression history 1
Injection site complications: Pain, hematoma, hemorrhage (rarely requiring transfusion/surgery) 1
Contraindications
- Hypersensitivity to goserelin or GnRH analogs 1
- Pregnancy (except for advanced breast cancer treatment) 1
Clinical Pearls
Cervical resistance: May increase during treatment—use caution when dilating cervix for endometrial ablation 1
Menopausal status monitoring: Cannot determine menopausal status while receiving ovarian suppression; monitor estradiol and FSH/LH levels if under 60 years and amenorrheic 3
Combination therapy considerations:
- When combining with tamoxifen and chemotherapy, give chemotherapy first, then sequential tamoxifen 3
- For aromatase inhibitors: Start OFS alone for 1-2 cycles until estradiol reaches postmenopausal range before adding AI 3
No dose adjustment needed for renal or hepatic impairment 1